Drug Type Monoclonal antibody |
Synonyms ABBV 514, ABBV-514 |
Target |
Action inhibitors |
Mechanism CCR8 inhibitor(C-C motif chemokine receptor 8 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastroesophageal junction adenocarcinoma | Phase 1 | United States | 01 Nov 2021 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | Japan | 01 Nov 2021 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | Israel | 01 Nov 2021 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | South Korea | 01 Nov 2021 | |
Gastroesophageal junction adenocarcinoma | Phase 1 | Taiwan Province | 01 Nov 2021 | |
Microsatellite Stable Colorectal Carcinoma | Phase 1 | United States | 01 Nov 2021 | |
Microsatellite Stable Colorectal Carcinoma | Phase 1 | Japan | 01 Nov 2021 | |
Microsatellite Stable Colorectal Carcinoma | Phase 1 | Israel | 01 Nov 2021 | |
Microsatellite Stable Colorectal Carcinoma | Phase 1 | South Korea | 01 Nov 2021 | |
Microsatellite Stable Colorectal Carcinoma | Phase 1 | Taiwan Province | 01 Nov 2021 |